ImmPACT Bio to Present New Preclinical Data for CD19/CD20 Bispecific CAR-T Cell Therapy in Multiple Sclerosis
ImmPACT Bio to Present New Preclinical Data for CD19/CD20 Bispecific CAR-T Cell Therapy in Multiple Sclerosis IMPT-514’s dual CAR approach is designed to ablate B-cells and pathogenic CD20+ T cells for potential therapeutic benefit in MS LOS ANGELES, May 21, 2024 – ImmPACT Bio USA Inc. (ImmPACT Bio), a clinical-stage biopharmaceutical company developing a new […]
ImmPACT Bio to Present New Ex Vivo Preclinical Data for Bispecific Claudin 18.2/TGF-β CAR T Program at the American Society of Gene & Cell Therapy 27th Annual Meeting
ImmPACT Bio to Present New Ex Vivo Preclinical Data for Bispecific Claudin 18.2/TGF-β CAR T Program at the American Society of Gene & Cell Therapy 27th Annual Meeting Novel dual CAR approach is designed to enhance CAR T-cell activity in solid tumors by addressing immune suppression in the tumor microenvironment LOS ANGELES, April 22, 2024 […]
ImmPACT Bio to Participate at the 2024 Cell and Gene Meeting on the Med Conference
ImmPACT Bio to Participate at the 2024 Cell and Gene Meeting on the Med Conference LOS ANGELES, Calif., March 26, 2024 – ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2024 […]
ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus
ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus IMPT-514 is the first-and-only CD19/CD20 CAR T-cell therapy in development for lupus Designed to reset the immune system, IMPT-514 is a one-time treatment option with potential to replace […]
HER2 and HLA-A*02 Dual CAR-T Cells Utilize LOH in a NOT Logic Gate to Address On-Target Off-Tumor Toxicity
ImmPACT Bio is pleased to announce the publication of their work in the Journal of ImmunoTherapy of Cancer regarding NOT logic gated CAR T cells for limiting on-target off-tumor toxicity titled, “HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity”. This work demonstrates that inhibitory CAR […]
